Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(1;21)(p22;q22) RUNX1/CLCA2

Written2012-06Amélie Giguçre, Josée Hébert
Quebec Leukemia Cell Bank, Division of Hematology-Oncology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, H1T 2M4, Canada

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9920/3 Therapy-related myeloid neoplasms
Atlas_Id 1608
 
  Partial GTG-banded karyotype showing derivative chromosomes 1 and 21 involved in the t(1;21)(p22;q22).

Clinics and Pathology

Disease Therapy-related acute myeloid leukemia (t-AML)
Epidemiology Two AML cases positive for the t(1;21)(p22;q22) were reported, a 9 year-old boy (Nadal et al., 2008) and a 64 year-old man (Giguère and Hébert, 2010).
Clinics The 9 year-old boy presented in September 2004 with an initial diagnosis of acute myeloid leukemia with maturation (AML-M2) with a normal karyotype. In December 2004, he underwent an allogeneic bone marrow transplantation and then relapsed in June 2006. At relapse, the karyotype was 46,XY,t(1;21)(p22;q22)[15]/46,XX[5].
The adult patient developed a de novo AML-M2 with an abnormal karyotype 45,XY,-7[17]/46,XY[3] in December 2005. He received a standard induction and consolidation chemotherapy followed by an allogeneic hematopoietic stem cell transplantation. In August 2007, he developed a t(1;21)(p22;q22) positive t-AML. Complete blood count showed a white blood cell count of 16.4 x 109/L, hemoglobin of 86 g/L and platelet count of 34 x109/L. The bone marrow aspirate showed 52% of blast cells.
Treatment The pediatric patient was treated with cytarabine, mitoxantrone and amsacrine. At complete remission, he underwent an allogeneic stem cell transplantation with a conditioning regimen including etoposide and total body irradiation. At relapse, the boy underwent a second bone marrow transplantation.
The adult patient was treated with a standard induction chemotherapy regimen (infusional cytarabine combined with daunorubicine) and two cycles of consolidation therapy with high doses cytarabine, followed by a reduced intensity allogeneic stem cell transplantation. The t(1;21) positive t-AML was not treated with chemotherapy. The patient received palliative care.
Evolution The boy was alive in April 2012 (Nadal, personal communication). The adult patient died one month and 18 days following t-AML development.
Prognosis Undetermined.

Genetics

FLT3-ITD (FLT3 internal tandem duplication) mutation was detected in the pediatric patient's leukemic cells and was absent in the adult patient's cells.

Cytogenetics

Cytogenetics Morphological Can be easily identified using G-banded chromosomes.
Cytogenetics Molecular FISH using the RUNX1-RUNX1T1 probe showed splitted signals located on derivative chromosomes 1 and 21. RUNX1 rearrangement was confirmed using the RP11-299D9 BAC probe (BACPAC Resources Center) (Giguère and Hébert, 2010).
 
  Metaphasic FISH using the LSI RUNX1-RUNX1T1 dual color translocation probe (Abbott Molecular). Three green signals (21q22, RUNX1 gene) are shown (arrows), indicating the presence of a RUNX1 rearrangement. Two normal red signals (8q22, RUNX1T1 gene) were observed.
Additional anomalies The t(1;21) was the sole anomaly in t-AML cells.

Genes involved and Proteins

Gene NameRUNX1 (runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene))
Location 21q22.12
 
  The RUNX1 gene and protein are represented. Exons 3 to 5 code for the DNA binding Runt homology domain (RHD) whereas exons 7 and 8 encode the transcriptional regulatory domain which includes activation (TA) and inhibitory domains (ID).
Dna / Rna The RUNX1 gene contains 8 coding exons spanning 260 kilobases (kb) of genomic DNA. Transcription orientation: telomere to centromere.
Protein RUNX1 is a conserved member of the RUNX family and is a master regulator of hematopoiesis through activation or repression of lineage-specific genes.
Gene NameCLCA2 (chloride channel accessory 2)
Location 1p22.3
 
  The CLCA2 gene and protein are represented. The calcium-activated chloride channel (CLCA), the von Willebrand factor type A domain (VWA) and a domain of unknown function (DUF1973) are encoded by amino acids 8 to 265, 312 to 470 and 494 to 674 respectively, according to the PFAM website (http://pfam.sanger.ac.uk).
Dna / Rna The CLCA2 gene contains 14 exons which spans 32 kb of genomic DNA. Transcription orientation: telomere to centromere.
Protein CLCA2 is a member of the calcium-activated chloride channel family. The protein was proposed to function as a regulator of chloride current and to act as a potential tumor suppressor in breast cancer cells (Gruber and Pauli, 1999; Elble and Pauli, 2001).

Result of the chromosomal anomaly

Hybrid gene
  Main fusion transcript resulting in a fusion of RUNX1 exons 1-6 to CLCA2 exons 2-14.
 
Description 5' RUNX1-CLCA2 3'.
Transcript At least six out-of-frame fusion transcripts were identified (Giguère and Hébert, 2010).
  
Fusion Protein
Note In this case, RUNX1-CLCA2 fusion transcripts lead to truncated RUNX1 proteins (Giguère and Hébert, 2010).
  

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:
you are welcome to submit a paper to our new Case Report section.

Bibliography

Tumor suppression by a proapoptotic calcium-activated chloride channel in mammary epithelium.
Elble RC, Pauli BU.
J Biol Chem. 2001 Nov 2;276(44):40510-7. Epub 2001 Aug 1.
PMID 11483609
 
CLCA2, a novel RUNX1 partner gene in a therapy-related leukemia with t(1;21)(p22;q22).
Giguere A, Hebert J.
Cancer Genet Cytogenet. 2010 Oct 15;202(2):94-100.
PMID 20875871
 
Tumorigenicity of human breast cancer is associated with loss of the Ca2+-activated chloride channel CLCA2.
Gruber AD, Pauli BU.
Cancer Res. 1999 Nov 1;59(21):5488-91.
PMID 10554024
 
RUNX1 rearrangements in acute myeloblastic leukemia relapsing after hematopoietic stem cell transplantation.
Nadal N, Stephan JL, Cornillon J, Guyotat D, Flandrin P, Campos L.
Cancer Genet Cytogenet. 2008 Jan 15;180(2):168-9.
PMID 18206548
 

Citation

This paper should be referenced as such :
Gigu&ère, A ; Hébert, J
t(1;21)(p22;q22) RUNX1/CLCA2
Atlas Genet Cytogenet Oncol Haematol. 2012;16(11):852-855.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/t0121p22q22ID1608.html


Translocations implicated (Data extracted from papers in the Atlas)

 t(1;21)(p22;q22) RUNX1/CLCA2

External links

RUNX1 (21q22.12) CLCA2 (1p22.3)

RUNX1 (21q22.12) CLCA2 (1p22.3)

Mitelman databaset(1;21)(p22;q22) [Case List]    t(1;21)(p22;q22) [Association List] Mitelman database (CGAP - NCBI)
arrayMapTopo ( C42) Morph ( 9920/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
Mitelman databaseRUNX1/CLCA2 [MCList]  RUNX1 (21q22.12) CLCA2 (1p22.3)
TICdbRUNX1/CLCA2  RUNX1 (21q22.12) CLCA2 (1p22.3)
 
Disease databaset(1;21)(p22;q22) RUNX1/CLCA2
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Sep 18 17:19:09 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.